GSK plc (NYSE:GSK) Position Increased by Premier Path Wealth Partners LLC

Premier Path Wealth Partners LLC grew its position in shares of GSK plc (NYSE:GSK) by 21.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 34,274 shares of the pharmaceutical company’s stock after purchasing an additional 5,967 shares during the quarter. Premier Path Wealth Partners LLC’s holdings in GSK were worth $1,159,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Eastern Bank acquired a new position in shares of GSK in the 3rd quarter worth approximately $26,000. Sunbelt Securities Inc. raised its holdings in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares during the period. Concord Wealth Partners grew its position in GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares in the last quarter. ST Germain D J Co. Inc. raised its stake in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the period. Finally, Fortitude Family Office LLC purchased a new stake in shares of GSK in the third quarter valued at $42,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GSK. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 13th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Up 0.0 %

GSK stock opened at $33.46 on Friday. The business’s 50-day simple moving average is $34.08 and its 200 day simple moving average is $38.01. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The company has a market cap of $69.34 billion, a PE ratio of 21.72, a price-to-earnings-growth ratio of 1.44 and a beta of 0.63. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were paid a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.70%. This is a positive change from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, November 15th. GSK’s dividend payout ratio is presently 96.10%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.